MONITORING DIFFUSE LARGE B-CELL LYMPHOMA FROM PERIPHERAL BLOOD SAMPLES
The invention is directed to sequencing-based methods for monitoring a minimal residual disease of a diffuse large B cell lymphoma (DLBCL) by one or more clonotypes correlated with the disorder. In some embodiments, such methods comprise the following steps: (a) obtaining a sample of peripheral blood from the patient; (b) amplifying molecules of nucleic acid from the sample, the molecules of nucleic acid comprising recombined DNA sequences from immunoglobulin genes; (c) sequencing the amplified molecules of nucleic acid to form a clonotype profile; and (d) determining from the clonotype profile a presence, absence and/or level of one or more patient-specific clonotypes correlated with the DLBCL and phylogenic clonotypes thereof.
1 . A method of monitoring diffuse large B-cell lymphoma (DLBCL) disease in a patient, the method comprising the steps of:
(a) determining one or more patient-specific clonotypes correlated with the DLBCL from a diagnostic sample;
(b) obtaining a peripheral blood sample from the patient comprising B-cells and/or cell-free nucleic acids;
(c) amplifying nucleic acid molecules from the B-cells and/or the cell-free nucleic acids of the peripheral blood sample, the nucleic acid molecules comprising recombined DNA sequences from immunoglobulin genes or nucleic acids transcribed therefrom;
(d) sequencing the amplified nucleic acid molecules to form a clonotype profile; and
(e) determining from the clonotype profile a presence, absence and/or level of the one or more patient-specific clonotypes correlated with the DLBCL, including previously phylogenic clonotypes thereof.
2 . The method of claim 1 wherein said diagnostic sample is a peripheral blood sample.
3 . The method of claim 2 wherein said nucleic acid molecules are from a cell free fraction of said peripheral blood sample.
4 . The method of claim 1 wherein said diagnostic sample is a tumor sample.
5 . The method of claim 1 further including the step of repeating said steps (b) through (e) to monitor DLBCL residual disease in said patient.
6 . The method of claim 5 wherein each of said clonotype profiles from said peripheral blood sample includes every clonotype present at a frequency of 0.1 percent or greater with a probability of ninety-nine percent.
7 . The method of claim 5 wherein each of said clonotype profiles from said peripheral blood sample includes every clonotype present at a frequency of 0.01 percent or greater with a probability of ninety-nine percent.
8 . The method of claim 5 wherein in said step of amplifying includes amplifying said nucleic acid molecules from a peripheral blood sample comprising at least 10 5 B cells.
9 . The method of claim 5 wherein in said step of amplifying includes amplifying said nucleic acid molecules from a peripheral blood sample comprising at least 10 6 B cells.
10 . A method of monitoring a diffuse large B-cell lymphoma (DLBCL) in a patient by one or more patient-specific clonotypes correlated with the DLBCL, the method comprising the steps of:
(a) obtaining a peripheral blood sample from the patient, the sample comprising B-cells and/or cell-free nucleic acids;
(b) extracting a nucleic acid sample from the peripheral blood sample;
(c) amplifying in a polymerase chain reaction nucleic acid molecules from the nucleic acid sample, the nucleic acid molecules encoding a VDJ region of an IgH or a portion thereof;
(c) sequencing the amplified nucleic acid molecules to form a clonotype profile; and
(d) determining from the clonotype profile a level of each of the one or more patient-specific clonotypes correlated with the DLBCL, wherein such levels include phylogenic clonotypes of each of such one or more patient-specific clonotypes.
11 . The method of claim 10 wherein said step of sequencing includes generating sequence reads in a range of from 20 to 400 nucleotides for determining a sequence of each clonotype.
12 . The method of claim 10 further including a step of treating said patient by transplanting bone marrow based on said level of said one or more patient-specific clonotypes.
13 . The method of claim 12 wherein said transplanting is implemented whenever said level of said one or more patient-specific clonotypes and phylogenic clonotypes thereof exceeds fifty percent of a level of said one or more patient-specific clonotypes in a diagnostic sample.
14 . The method of claim 10 further including the step of repeating said steps (a) through (d) to monitor DLBCL residual disease in said patient.
15 . The method of claim 14 wherein each of said clonotype profiles from said peripheral blood sample includes every clonotype present at a frequency of 0.1 percent or greater with a probability of ninety-nine percent.
16 . The method of claim 14 wherein each of said clonotype profiles from said peripheral blood sample includes every clonotype present at a frequency of 0.01 percent or greater with a probability of ninety-nine percent.
17 . The method of claim 14 wherein in said step of amplifying includes amplifying said nucleic acid molecules from a peripheral blood sample comprising at least 10 5 B cells.
18 . The method of claim 14 wherein in said step of amplifying includes amplifying said nucleic acid molecules from a peripheral blood sample comprising at least 10 6 B cells.
19 . The method of claim 10 wherein said step of obtaining said peripheral blood sample further including depleting said peripheral blood sample of granulocytes.